Agenus Inc. (NASDAQ:AGEN) shares saw an uptick in trading volume on Thursday . 1,026,970 shares traded hands during mid-day trading, an increase of 5% from the previous session’s volume of 982,088 shares.The stock last traded at $4.65 and had previously closed at $4.46.

A number of brokerages have weighed in on AGEN. Zacks Investment Research raised shares of Agenus from a “sell” rating to a “hold” rating in a report on Tuesday. Maxim Group reissued a “buy” rating and issued a $7.00 price target on shares of Agenus in a report on Friday, June 10th. Finally, HC Wainwright reissued a “buy” rating on shares of Agenus in a report on Saturday, April 30th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Agenus presently has an average rating of “Buy” and a consensus price target of $10.47.

The company’s market cap is $416.16 million. The stock has a 50 day moving average of $4.12 and a 200-day moving average of $3.78.

Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, April 28th. The company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.14. Analysts expect that Agenus Inc. will post ($1.41) earnings per share for the current year.

In other news, CEO Garo H. Armen purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The shares were acquired at an average price of $3.18 per share, for a total transaction of $318,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,346,026 shares in the company, valued at $4,280,362.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

A hedge fund recently raised its stake in Agenus stock. Wells Fargo & Company MN boosted its stake in shares of Agenus Inc. (NASDAQ:AGEN) by 177.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 332,554 shares of the company’s stock after buying an additional 212,599 shares during the period. Wells Fargo & Company MN owned 0.39% of Agenus worth $1,510,000 as of its most recent SEC filing.

Agenus Inc (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.